questionText: To ask the Secretary of State for Health and Social Care, if he will make an estimate of the (a) cost per patient, (b) number of eligible patients, (c) net cost, (d) incremental quality-adjusted life years gained and (e) incremental cost-effectiveness ratio of extending abiraterone access to high-risk, non-metastatic prostate cancer patients in England.
answerText: NHS England is unable to provide information related to the cost per patient as disclosure of this information could be used to identify the discounted price that we have agreed and would prejudice the commercial interests of both NHS England and the supp...
heading: Prostate Cancer: Abiraterone